Posted by SLS on February 5, 2014, at 21:46:20
In reply to Re: Scott (pretty long post), posted by poser938 on February 5, 2014, at 17:05:25
Hey, Poser.
You described your situation well.
A few ideas arranged in no particular order:
* Agomelatine (Vilazadone)? It is a potent 5-HT2c receptor antagonist without affecting the 5-HT2a receptor. This is in addition to stimulating melatonin receptors.
* Nortriptyline (Pamelor)? It combines NE reuptake inhibition with 5-HT2a receptor antagonism. It increases dopamine by stimulating its release.
* Mirtazapine (Remeron)? It combines 5-HT2a/c and 5-HT3 receptor antagonism with presynaptic NE alpha-2 receptor antagonism.
* Nefazodone (Serzone)? It combines 5-HTc receptor antagonism and weak serotonin reuptake inhibition.
* Trazodone (Deseryl)? It combines 5-HTc receptor antagonism and weak serotonin reuptake inhibition. Side effects limit its use, and the mCPP metabolite can produce anxiety and agitation in vulnerable individuals via 5-HT2c agonism.
* Memantine (Namenda)? It produces dopamine release, D2 receptor agonism, and dopamine reuptake inhibition.
* Amantadine (Symmetrel)? It increases dopaminergic activity and acts as an antagonist of the NMDA glutamate receptor.
* Aripiprazole (Abilify)? It acts as a dopamine system stabilizer via dopamine D2/3 receptor partial agonism. It also acts as a 5-HT1a partial agonist and 5-HT2a receptor antagonist.
* Selegiline (Emsam)? It is an irreversible MAO inhibitor that is selective for the MAO-B (dopamine) enzyme at low dosages.
* Tranylcypromine (Parnate)? It is an irreversible and nonselective MAO inhibitor with amphetamine-like properties.
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.- George Bernard Shaw
poster:SLS
thread:1060040
URL: http://www.dr-bob.org/babble/20140123/msgs/1060305.html